<DOC>
	<DOCNO>NCT00976937</DOCNO>
	<brief_summary>The purpose study evaluate benefit risk lixisenatide ( AVE0010 ) , comparison sitagliptin , add-on treatment metformin , obese ( body mass index [ BMI ] great equal 30 kilogram per square meter [ kg/m^2 ] ) type 2 diabetic patient le 50 year age , period 24 week treatment . The primary objective study assess efficacy lixisenatide , comparison sitagliptin , add-on treatment metformin composite endpoint glycemic control term glycosylated hemoglobin ( HbA1c ) body weight , Week 24 . Secondary objective assess effect lixisenatide , comparison sitagliptin , add-on treatment metformin absolute change HbA1c value body weight ; fast plasma glucose ( FPG ) ; plasma glucose , insulin , C-peptide , glucagon , proinsulin 2-hour standardized meal test ; insulin resistance assess homeostatic model assessment insulin resistance ( HOMA-IR ) ; beta cell function assess homeostatic model assessment beta-cell function ( HOMA-beta ) ; evaluate safety , tolerability , anti-lixisenatide antibody development .</brief_summary>
	<brief_title>24-week Study Comparing Lixisenatide Sitagliptin add-on Metformin Obese Type 2 Diabetic Patients Younger Than 50 Years</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion Type 2 diabetes mellitus , diagnose least 1 year time screen visit , insufficiently control metformin stable dose least 1.5 gram/day ( g/day ) least 3 month prior screen visit Patients obesity ( BMI great equal [ &gt; = ] 30 kg/m^2 ) age 18 year less 50 year Exclusion criteria HbA1c le ( &lt; ) 7.0 percent ( % ) HbA1c great ( &gt; ) 10 % screen Type 1 diabetes mellitus Pregnant breastfeed woman woman childbearing potential effective contraceptive method FPG screen &gt; 250 milligram/deciliter ( mg/dL ) ( &gt; 13.9 millimole/ liter [ mmol/L ] ) Weight change 5 kg 3 month precede screen visit History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease , personal family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC ( example , multiple endocrine neoplasia syndrome ) History metabolic acidosis , include diabetic ketoacidosis within 1 year prior screen Hemoglobinopathy hemolytic anemia receipt blood plasma product within 3 month prior time screen Within last 6 month prior screen : history myocardial infarction , stroke , heart failure require hospitalization Known history drug alcohol abuse within 6 month prior time screen Any clinically significant abnormality identify physical examination , laboratory test , electrocardiogram ( ECG ) vital sign time screen judgment investigator subinvestigator could preclude safe completion study constrain efficacy assessment major systemic disease , presence clinically significant diabetic retinopathy presence macular edema likely require laser treatment within study period Uncontrolled inadequately control hypertension time screen rest systolic diastolic blood pressure &gt; 180 millimeter mercury ( mmHg ) &gt; 110 mmHg , respectively Laboratory finding time screening : Amylase and/or lipase &gt; 3 time upper limit normal ( ULN ) laboratory range ; alanine aminotransferase ( ALT ) : &gt; 3 time ULN ; total bilirubin : &gt; 1.5 time ULN ( except case Gilbert 's syndrome ) ; hemoglobin &lt; 11 gram/deciliter and/or neutrophil &lt; 1500 per cubic millimeter ( mm^3 ) and/or platelet &lt; 100 000/mm^3 ; positive test Hepatitis B surface antigen ( HBsAg ) and/or Hepatitis C antibody ( HCAb ) , positive serum pregnancy test female childbearing potential , calcitonin &gt; =20 picogram per milliliter ( pg/mL ) ( 5.9 picomole per liter ) Patients consider investigator subinvestigator inappropriate study reason ( example , impossibility meet specific protocol requirement [ schedule visit , able selfinjections ] , likelihood require treatment screen phase treatment phase drug permit clinical study protocol , investigator subinvestigator , pharmacist , study coordinator , study staff relative thereof directly involve conduct protocol ) Use oral injectable antidiabetic hypoglycemic agent metformin ( example , sulfonylurea , alpha glucosidase inhibitor , thiazolidinedione , exenatide , dipeptidyl peptidase IV ( DPPIV ) inhibitor , insulin ) within 3 month prior time screen History bariatric surgery , antiobesity treatment , unstable diet within 3 month prior time screen Use systemic glucocorticoid ( exclude topical application inhale form ) one week within 3 month prior time screen Use investigational drug within 3 month prior screen Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include ( limited ) : gastroparesis , unstable ( , worsen ) control ( , prolong nausea vomit ) gastroesophageal reflux disease require medical treatment , within 6 month prior time screen Any previous treatment lixisenatide ( example , participation previous study lixisenatide ) Allergic reaction glucagon like peptide1 ( GLP 1 ) agonist past ( example , exenatide , liraglutide ) metacresol History serious hypersensitivity reaction sitagliptin Moderate severe renal impairment ( creatinine clearance inferior 50 milliliter/minute [ mL/min ] ) Additional exclusion criterion end runin phase : informed consent withdrawal ; lack compliance singleblind placebo runin period ( &gt; 2 injection miss &gt; 2 capsule miss ) ; patient adverse event could preclude inclusion study , assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>